CJ-005

CJ-005 is a **nanocrystal formulation** of the alkylating agent **busulfan**, currently in **preclinical** development by **Guangdong Xijie Pharmaceutical**. Classified as a Class 2.2 improved new drug in China, CJ-005 utilizes proprietary nanocrystal technology to optimize the delivery and stability of busulfan. The drug is intended for use in high-dose conditioning regimens prior to hematopoietic stem cell transplantation (HSCT) for patients with **leukemia** and **lymphoma**. By creating a nanocrystal suspension, the formulation aims to improve the solubility of the active ingredient and potentially reduce the toxicity associated with conventional organic solvents or surfactants used in standard busulfan injections.

Other names

busulfan nanocrystalbusulfan nanocrystal injection